 |
|
Low-dose chemotherapy plus antiangiogenesis drug has activity in advanced breast cancer
December 09, 2005Chemotherapy given in low, frequent doses - a novel strategy called "metronomic" delivery - achieved partial shrinkage of disease in some advanced breast cancer patients when given concurrently with an angiogenesis inhibitor, report researchers from Dana-Farber Cancer Institute in Boston.
In a pilot study of 55 patients, the combination of low-dose chemotherapy and the anti-VEGF antibody, bevacizumab (Avastin; Genentech) delayed the breast cancer's progression by an average of 5 ½ months, compared to two months with the low-dose chemotherapy alone, said Harold Burstein, MD, PhD, a medical oncologist at Dana-Farber. He will present the results in a General Session at the annual San Antonio Breast Cancer Symposium on Thursday, Dec. 8.
"Pairing metronomic therapy with a dedicated angiogenesis inhibitor showed clinical activity, and was quite well tolerated," said Burstein. "We think this is a combination worth pursuing and are exploring this treatment concept further in a Phase II study, which extends these treatments into early stage breast cancer therapy."
The current study is one of the first rigorous tests of a treatment strategy that was proposed several years ago as a means of improving the results of chemotherapy for breast cancer, said Burstein, who is also an assistant professor of medicine at Harvard Medical School.
Historically, high doses of chemotherapy are given at intervals of two to three weeks, with time off the drug to recover from side effects. However, laboratory researchers have suggested that this rest period also allows the blood vessels feeding the tumor to re-form after they had been destroyed by the chemotherapy. They proposed giving smaller, almost constant doses of the drug - as regular as the ticking of a metronome - as a way to hamper angiogenesis (the growth of new blood vessels).
In the Dana-Farber study, the chemotherapy drugs cyclophosphamide and methotrexate were given in a metronomic regimen to 21 patients with advanced, metastatic breast cancer. In another 34 patients, the chemotherapy was paired with the angiogenesis inhibitor bevacizumab, or Avastin, given intravenously every 14 days. None of the patients had been previously heavily treated for their advanced cancer.
The metronomic-alone therapy led to two partial responses (10 percent of the patients), while in another eight patients the cancer remained stable. Results seemed better in the combination group, in which 10 patients (29 percent) had partial responses, while 14 (41 percent) experienced stable disease. There were still some side effects in both groups, including fatigue, but Burstein said the therapies were generally well tolerated and lacked the major side effects of traditional chemotherapy such as gastrointestinal and hair loss.
The researchers concluded that the metronomic therapy by itself had limited clinical activity, but the activity seen when the antiangiogenesis drug was added suggests "further investigation of this novel treatment study is warranted."
Dana-Farber Cancer Institute
The current study is one of the first rigorous tests of a treatment strategy that was proposed several years ago as a means of improving the results of chemotherapy for breast cancer, said Burstein, who is also an assistant professor of medicine at Harvard Medical School.
Historically, high doses of chemotherapy are given at intervals of two to three weeks, with time off the drug to recover from side effects. However, laboratory researchers have suggested that this rest period also allows the blood vessels feeding the tumor to re-form after they had been destroyed by the chemotherapy. They proposed giving smaller, almost constant doses of the drug - as regular as the ticking of a metronome - as a way to hamper angiogenesis (the growth of new blood vessels).
In the Dana-Farber study, the chemotherapy drugs cyclophosphamide and methotrexate were given in a metronomic regimen to 21 patients with advanced, metastatic breast cancer. In another 34 patients, the chemotherapy was paired with the angiogenesis inhibitor bevacizumab, or Avastin, given intravenously every 14 days. None of the patients had been previously heavily treated for their advanced cancer.
The metronomic-alone therapy led to two partial responses (10 percent of the patients), while in another eight patients the cancer remained stable. Results seemed better in the combination group, in which 10 patients (29 percent) had partial responses, while 14 (41 percent) experienced stable disease. There were still some side effects in both groups, including fatigue, but Burstein said the therapies were generally well tolerated and lacked the major side effects of traditional chemotherapy such as gastrointestinal and hair loss.
The researchers concluded that the metronomic therapy by itself had limited clinical activity, but the activity seen when the antiangiogenesis drug was added suggests "further investigation of this novel treatment study is warranted."
Dana-Farber Cancer Institute
Chemotherapy Current Events and Chemotherapy News RSSSensitive nanowire disease detectors made by Yale scientists
Yale scientists have created nanowire sensors coupled with simple microprocessor electronics that are both sensitive and specific enough to be used for point-of-care (POC) disease detection, according to a report in Nano Letters.
On the trail of a targeted therapy for blood cancers
nvestigators from the Herman B Wells Center for Pediatric Research at the Indiana University School of Medicine are focusing on a family of blood proteins that they hope holds a key to decreasing the toxic effects of chemotherapy in children and adults.
Hodgkin lymphoma -- new characteristics discovered
Researchers are still discovering new characteristics of Hodgkin lymphoma, a common form of cancer of the lymphatic system. The malignant cells are derived from white blood cells (B cells), but have lost a considerable part of the B cell-specific gene expression pattern.
Bisphenol A linked to chemotherapy resistance
Exposure to bisphenol A (BPA) may reduce the effectiveness of chemotherapy treatments, say University of Cincinnati (UC) scientists.
Pediatric study finds alternatives for radiation of low-grade brain tumors
A multi-institutional study led by researchers at The University of Texas M. D. Anderson Cancer Center has found that using chemotherapy alone and delaying or avoiding cranial radiation altogether can be effective in treating pediatric patients with unresectable or progressive low-grade glioma.
Mayo researchers explore issues related to multiple myeloma treatment
Multiple myeloma (MM) is a cancer of plasma cells that affects approximately 3 in 100,000 people each year. Although there is no cure for this disease, researchers have developed treatments that help relieve pain, control complications, and slow the progress of MM in many patients.
News from Cancer: Disparities in head and neck cancer patients
A new analysis finds considerable disparities in survival related to race and socio-economic status among patients with head and neck cancer.
Nanodiamond drug device could transform cancer treatment
A Northwestern University research team has developed a promising nanomaterial-based biomedical device that could be used to deliver chemotherapy drugs locally to sites where cancerous tumors have been surgically removed.
Children's National researchers develop novel anti-tumor vaccine
A novel anti-tumor vaccine for neuroblastoma and melanoma developed by scientists and clinicians at Children's National Medical Center in collaboration with investigators from the University of Iowa is showing significant impact on tumor growth in mice.
Surgical treatment provides new option for some colorectal cancer patients
Research out of Wake Forest University School of Medicine suggests that a surgical technique not traditionally used in advanced abdominal cancer may be a viable treatment option for some patients previously thought to be untreatable, offering the real possibility of extending survival for those patients.
More Chemotherapy Current Events and Chemotherapy News Articles
 | The Chemotherapy & Radiation Therapy Survival Guide (Chemotherapy and Radiation Therapy Survivor's Guide) by Judith McKay, Nancee Hirano |
 | Physician's Cancer Chemotherapy Drug Manual 2008 (Jones and Bartlett Series in Oncology) by Edward Chu, Vincent T. DeVita Jr. Completely revised and updated for 2008, this practical handbook is an up-to-date guide to all aspects of cancer chemotherapy. The book provides a comprehensive, easy to use catalogue of over 100 drugs-both on- and off-label-commonly used in cancer treatment. A section on Common Chemotherapy Regimens provides a quick reference to management of specific cancers, arranged... |
 | Chemotherapy and Radiation For Dummies by Alan P. Lyss, Humberto Fagundes, Patricia Corrigan An informative, compassionate guide for cancer patients and their loved ones Each year, more than 1 million people get treated for cancer, and most of these will undergo chemotherapy, radiation therapy, or both. This reassuring, optimistic guide helps people get a handle on treatment options and explains in plain English how chemotherapy and radiation therapy really work. It offers detailed... |
 | Chemotherapy Heals Cancer and the World is Flat by Lothar Hirneise In the future there will be two groups of cancer patients. Those who have read this book - and those who are uninformed. For many years Lothar Hirneise has been traveling throughout the world looking for the most successful cancer therapies, and he has been explaining to people that there is much more available than just chemotherapy and irradiation. Recognized internationally as Europe's leading... |
 | Questioning Chemotherapy by Ralph W. Moss A revealing critique of chemotherapy, this book looks objectively at chemo's successes and... |
 | Coping with Chemotherapy: Compassionate Advice and Authoritative Information from a Chemotherapy Survivor by Nancy Bruning After undergoing chemotherapy herself, author Nancy Bruning decided to write a candid and authoritative book to fill the void of information available for patients facing this procedure. In this completely revised, updated, and thoroughly researched edition, she details every step of the process, providing information even doctors neglect to tell their patients, including possible sexual and... |
 | Coping With Chemotherapy and Radiation Therapy by Daniel Cukier New advances in treatment offer cancer patients more options than ever before. Coping with Chemotherapy and Radiation is an accessible, accurate guide to the latest developments in radiation therapy and chemotherapy. You will find important information on how chemotherapy and radiation treatments work; what to expect from treatments, how to alleviate common side effects, and... |
 | Chemotherapy and Biotherapy Guidelines and Recommendations for Practice (second edition) Order your copy of the newly revised and updated second edition of your #1 resource for chemotherapy administration! With more than 46,000 copies sold since 2001, you and thousands of your colleagues in oncology nursing have studied and consulted the information found in the first edition. The new second edition is based on current evidence and has been revised and updated to reflect the... |
 | Pocket Guide to Chemotherapy Protocols, Fourth Edition (Pocket Guide to Chemotherapy Protocols) by Edward Chu An indispensable quick reference for physicians, nurses, and other healthcare providers treating cancer patients! The updated Fourth Edition of the best-selling Pocket Guide to Chemotherapy Protocols is spiral bound and arranged alphabetically by cancer type for easy access, and contains combination as well as selected single-agent regimens for solid tumors and hematologic malignancies. In each... |
 | The Cancer Chemotherapy Handbook (6th Edition) by David S. Fischer, Henry J. Durivage, M. Tish Knobf, Nancy Beaulieu Here's a comprehensive, yet compact and practical guide to the care and chemotherapeutic treatment of cancer patients. It encompasses all major chemotherapeutic agents and combinations, investigational and newly approved drugs, and describes their mechanisms of action, indications, metabolism, dose, administration, toxicity, and drug interactions and incompatibilities. The 6th Edition includes... |
| © 2008 BrightSurf.com |